# Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma

> **NCT03927222** · PHASE2 · TERMINATED · sponsor: **Mustafa Khasraw, MBChB, MD, FRCP, FRACP** · enrollment: 6 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **BIOLOGICAL:** Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF
- **DRUG:** Temozolomide
- **BIOLOGICAL:** Tetanus-Diphtheria Toxoid (Td)
- **BIOLOGICAL:** GM-CSF
- **BIOLOGICAL:** 111-Indium-labeling of Cells for in vivo Trafficking Studies

## Key facts

- **NCT ID:** NCT03927222
- **Lead sponsor:** Mustafa Khasraw, MBChB, MD, FRCP, FRACP
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-09-30
- **Primary completion:** 2023-02-10
- **Final completion:** 2023-02-10
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Resource shortage
- **Last updated:** 2024-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03927222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03927222, "Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT03927222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*